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ABSTRACT
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma comprising a heterogeneous group 
of disorders with variable histological and clinical behavior. Although other lymphomas may present in the leukemic phase 
more frequently, this appearance is unusually observed among DLBCL cases. Diagnosing lymphoma is not always easy, 
and the patient’s clinical status quite often may hamper invasive procedures for diagnosis pushing the clinician to look 
for alternatives to reach the nearest possible accurate diagnosis. The authors report the case of a middle-aged man who 
presented the history of malaise, weight loss, and low-grade fever. The peripheral blood count showed leukocytosis with 
the presence of blasts and thrombocytopenia. The cytological morphology and immunophenotyping of the peripheral 
blood and bone marrow aspirate, as well as the bone marrow biopsy accompanied by a thorough immunohistochemical 
analysis, rendered the diagnosis of DLBCL in the leukemic phase. The patient was prescribed R-CHOP with a favorable 
outcome. Intra-abdominal lymph node biopsy was avoided because of the patient’s critical medical condition. The authors 
highlight this rare form of presentation of DLBCL as well as the combination of peripheral blood, bone marrow aspirate, 
and bone marrow biopsy for reaching the diagnosis in cases were a lymph node sample is unavailable for the diagnostic 
work-up.  
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CASE REPORT
A 60-year-old man was admitted to the emergency 
facility complaining of syncope following two episodes 
of melena that occurred the night before. He referred 
weight loss of 7 kg during the last 3 months (10% of 
his usual weight), and over the last week asthenia and 
low-grade fever. His past medical history included a 
sigmoidectomy for colonic adenocarcinoma 4 years 
ago, without evidence of relapse or metastatic disease. 
Article / Clinical Case Report
Autopsy and Case Reports 2016;6(1):41-45
Diffuse large B-cell lymphoma presenting in the leukemic phase
42
The physical examination disclosed a hydrated, pale, 
hypotensive, and tachycardic patient. The lungs and 
heart examinations were normal, and the abdomen 
showed an enlarged spleen. Mildly enlarged lymph 
nodes were palpable in the groin and bilaterally in the 
axillary region. During the examination, the patient 
presented episodes of vomiting and hematemesis. 
After hemodynamic stabilization with crystalloids 
and blood transfusion, an upper digestive endoscopy 
was undertaken, which showed a bleeding arteriolar 
stub in a normal gastric mucosa, classified as Forrest 
Ib (Dielafoy lesion). Bleeding was controlled with the 
aid of metallic hemoclips. The peripheral blood count, 
before the blood transfusion, showed hemoglobin 
of 3.9 g/dL (reference value [RV]: 13.5-17.5 g/dL), 
hematocrit of 12.5% (RV: 41-53%), and leukocytes 
count of 31,470/mm3 (RV: 4,500-11,000/ mm3) with 
19% of medium-sized cells characterized by basophilic 
cytoplasm, medium nucleus/cytoplasm relationship, 
loose chromatin, evident nucleolus (Figure 1A, B), and 
platelets of 52,000/mm3 (RV: 150,000-400,000/mm3). 
Lactate dehydrogenase determination was 2612 U/L 
(RV: 120-246 U/L). Bone marrow aspiration showed 
erythroid hyperplasia and 23.6% of lymphocytes with 
varied morphology–2.8% of which were represented 
by large-sized cells with medium nucleus/cytoplasm 
relationship, basophilic cytoplasm, and loose chromatin 
(Figure 1C, D). Renal function, electrolytes, hepatic 
enzymes, and coagulogram were normal.
The computed tomography (CT) of the abdomen 
and thorax showed heterogeneous, enlarged, and 
confluent lymph nodes measuring 4.1 × 1.6 cm in 
the retroperitoneum (periaortic, interaortocaval, and 
portocaval), and in the perigastric, peri-esophageal, 
and pericardic regions. The spleen was enlarged and 
exhibited heterogeneous attenuation coefficient 
(Figure 2). The axil lary lymph nodes measured 
1.5 × 1.3 cm
Immunophenotyping and cell morphology of 
bone marrow and peripheral blood samples resulted 
in mature monoclonal cells of B lineage consistent 
with leukemic large B-cell lymphoma (heterogeneous 
CD20+, CD79b++, CD79a+, mIgM-, cyIgM+, cykappa+, 
cylambda−, besides faint coexpression of CD200 and 
negativity for CD5.
During hospitalization, the patient presented daily 
high-grade fever (mostly in the evening) accompanied 
by diaphoresis.
Figure 1. Photomicrography of the peripheral blood smear A, B - and bone marrow aspiration smear; C, D - (Leishman 
stain), showing large cells with abundant basophilic cytoplasm, and nuclei with loose chromatin and evident 
nucleolus.
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An inguinal lymph node was biopsied and 
resulted in reactive lymphadenitis on histology. 
An intra-abdominal lymph node biopsy was not 
performed due to the patient’s poor clinical condition. 
A bone marrow biopsy showed massive lymphomatous 
cells infiltration (60-65%), composed by large 
cells–some of them with homogeneous eosinophilic 
cytoplasm (Figure 3). The immunohistochemical 
analysis was positive for CD20 and BCL-2, and negative 
for CD10 (Figure 3), CD5, CD10, Cycline-D1, and TdT. 
The Ki67 was 70%.
Therefore, the analysis of the bone marrow biopsy 
added to the peripheral and bone marrow cytology 
(morphology and immunophenotype) permitted the 
diagnosis of diffuse large B-cell lymphoma (DLBCL) 
in the leukemic phase. The Ann Arbor staging was IV 
(bone marrow and blood), and the revised International 
Prognostic Index (R-IPI) was 4 (LDH, ECOG 3, Stage IV, 
EN>1) regardless of the negative nodal confirmation. 
Other diagnoses, such as the indolent lymphomas 
(CD10 negative, Cyclin-D1 negative, CD5 negative) 
or even the precursor cell lymphomas/leukemias 
(TdT negative) could be ruled out.
The patient signed the informed consent form, 
authorizing the publication of this report.
DISCUSSION
Lymphomas differ from chronic lymphoid leukemia 
by the major or primary site of the disease, which is 
usually peripheral lymphoid tissues rather than bone 
marrow. However, bone marrow infiltration by 
neoplastic circulating cells may occur in lymphomas, 
such as in leukemia, giving rise to a leukemic phase.1 
This leukemic phase may take place during the 
lymphoma progression or rarely (in DLBCL) can be 
present at diagnosis, as occurred in the present case.
Although the diagnosis of lymphoma is based 
predominantly on histological examination of tissues, 
the presence of circulating lymphoma cells during 
the leukemic phase can give rise to the diagnosis, 
based on the cell’s immunophenotype analysis by flow 
cytometry. Interestingly, the lymph node biopsy in this 
case was negative for malignancy, showing that the 
site for biopsy was not suitable for the histological 
examination.
Figure 2. Abdominal CT showing lymphadenomegaly. A - Perigastric; B - Periportal space; C - Mesenteric region; 
D - Hepatosplenomegaly with perfusional heterogeneity in the spleen consistent with infarction.
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DLBCL is a heterogeneous group of disorders 
with variable histological and clinical behavior. It is 
characterized morphologically by the large atypical 
lymphoid cell appearance with pale blue cytoplasm; 
round, irregular, and vesicular nuclei with prominent 
nucleoli, and relatively abundant cytoplasm.2
Immunophenotypically, DLBCL is by definition, 
positive for B-lineage markers (mostly CD20) and 
variable immunoglobulin (surface or cytoplasmic). 
The follicle center cell markers CD10 and BCL6 are 
expressed in 40% and 60% of cases, respectively. 
Some cases may express post-germinal center cell or 
plasma cell-associated markers such as CD38, VS38, 
and MUM1. Up to 50% of the cases express the 
BCL-2 protein increasing the possibility of double hit 
lymphoma (when the positivity is confirmed by FISH 
on an MYC-related locus), which is related to a worse 
prognosis. A minority of DLBCs express CD30, usually 
in a heterogeneous pattern. CD5 is expressed in 10% 
of cases, and the Ki-67 is usually high.2
DLBCL accounts for 30-40% of the newly 
diagnosed adult non-Hodgkin lymphomas, but rarely 
presents a leukemic phase, which is different from 
other lymphomas where this feature is well-recognized, 
such as mantle cell lymphoma, follicular lymphoma, 
anaplastic large cell lymphoma, and in terminal phases 
of all refractory lymphomas.3,4 We searched on PubMed 
for DLBCL presenting in the leukemic phase, but could 
only retrieve publications of case reports or short series.
The pathologic mechanisms involving the 
migration of lymphoma cells into the bloodstream and, 
the reasons for different leukemic presentations among 
the different lymphomas are unclear. A differential 
expression of adhesion molecules was proposed as a 
possible mechanism for the migration of lymphocytes 
from the lymph nodes, but the current studies are not 
conclusive. The available data on DLBC do not support 
the hypothesis that a different profile of adhesion 
molecules plays a role in the pathogenesis of bone 
marrow involvement.5,6
Figure 3. Photomicrography of the bone marrow. A - Massive marrow infiltration by lymphoma cells (H&E, 100X); 
B - Lymphoma cells, composed of large atypical cells with blue cytoplasm; round, irregular and vesicular nuclei 
with prominent nucleoli; and abundant cytoplasm. Some cells present homogeneous eosinophilic cytoplasm (H&E, 
400X); C - Positivity for CD 20 in the lymphomatous cells (200X); D - Positivity for BCL-2 in the lymphomatous cells 
(400X).
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Patients with DLBC presenting in the leukemic 
phase are prone to have extranodal involvement 
besides the bone marrow, bearing a high tumor 
burden. Data from one cohort of 29 patients showed 
the involvement of the spleen in 62%, pleura/lung in 
41%, liver in 21%, bone in 17%, bowels in 7%, and 
cerebrospinal fluid in 14% of cases. Of these patients, 
90% received anthracycline-based regimens with 
rituximab, which was associated with early mortality 
(14% vs. 6% in patients with DLBCL treated with 
R-CHOP), but yields approximately 50% at the 4-year 
survival analysis, which is somehow comparable to 
the overall survival in patients with DLBCL and a high 
International Prognostic Index Score, and no leukemic 
presentation.5 There is no available data concerning 
randomized or prospective studies to guide the better 
treatment for these cases Currently, the therapeutic 
choice remains as rituximab and anthracycline-based 
protocols.
CONCLUSION
We described a rare clinical presentation of DLBCL 
with early leukemic phase, and highlighted the use of 
flow cytometry analysis of peripheral blood and bone 
marrow samples to perform the diagnosis.
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